Moleculin Biotech prices $4.5M registered direct offering and concurrent private placement

Moleculin Biotech, Inc.

Gross proceeds ~$4.5M from sale of 7,044,836 shares/pre-funded warrants at effective price of $0.64 (institutional) and $0.69 (insiders).
Concurrent private placement of warrants to purchase up to 14,089,672 common shares at $0.64, exercisable from stockholder approval, 5-year term.
Expected closing December 26, 2023; Maxim Group LLC serves as placement agent with 7% fee.
CEO, CFO, directors, and employees purchased 326,086 shares at $0.69 per unit, participating alongside institutional investor.
Company also amended bylaws to change voting standard to majority of votes cast for most stockholder matters.

item 1.01 item 3.02 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Moleculin Biotech, Inc.: The Board adopted the Fourth Amended and Restated Bylaws, including a clarification that matters presented to stockholders (other than director elections) shall be decided by the affirmative vote of a majority of votes cast (excluding abstentions and broker nonvotes) (effective 2023-12-20).

Change: bylaw amendment
Effective: 2023-12-20

Exact text from the filing

On December 20, 2023, the Board of Directors of the Company adopted the Fourth Amended and Restated Bylaws of Moleculin Biotech, Inc. (as amended and restated, the “Bylaws”), effective on such date.

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-035141

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.